Clinical trial
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of…
NCT00202982 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00202982 |
|---|---|
| Title | A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose |
| Official title | A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability and Safety of 40 mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapse-Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | glatiramer acetate 20 mg, glatiramer acetate 40 mg |
| Enrollment | 90 |
| Start date | Aug 1, 2003 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Sep 20, 2005 |
| Last update posted | Jan 14, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: